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Background: We compared risk factors and clinical characteristics, 9-year lung function change 
and hospitalization risk, across subjects with the asthma-COPD overlap syndrome (ACOS), asthma 
or COPD alone, or none of these diseases. 
Methods: Participants in the European Community Respiratory Health Survey in 1991-1993 (age 
20-44 years) and 1999-2001 were included. Chronic airflow obstruction was defined as pre-
bronchodilator FEV1/FVC<lower limit of normal on both occasions. Based on their history of 
respiratory symptoms, spirometry and risk factors, subjects were classified as having: asthma alone 
(n=941), COPD alone (n=166), ACOS (n=218) and none of these (n=5,659).  
Results: Subjects with ACOS shared risk factors and clinical characteristics with subjects with 
asthma alone, whereas they had an earlier age at asthma onset. FEV1 change in the ACOS group (-
25.9 mL/yr) was similar to that in the asthma group (-25.3 mL/yr), and lower (p<0.001) than in the 
COPD group (-37.3 mL/yr). ACOS was associated with the highest hospitalization rate. 
Conclusion: Among young adults aged 20-44 years, ACOS seems to represent a form of severe 
asthma, characterized by more frequent hospitalizations, and to be the result of early-onset asthma 
that has progressed to fixed airflow obstruction.  
 






ACOS, asthma-COPD overlap syndrome 
AHR, airway hyperresponsiveness 
BMI, body mass index 
COPD, chronic obstructive pulmonary disease 
ECRHS, European Community Respiratory Health Survey 
ER, emergency room 
ETS, environmental tobacco smoke 
FEV1, forced expiratory volume in 1 s 
FVC, forced vital capacity 
LLN, lower limit of normal 
 
"Take home" message: 
The asthma-COPD overlap syndrome in young adults is a form of early-onset severe asthma with 





Asthma and chronic obstructive pulmonary disease (COPD) are a major public health problem, and 
they co-exist in a large proportion of subjects.[1-6] Patients with the asthma-COPD overlap 
syndrome (ACOS) have a more rapid disease progression, more respiratory symptoms, 
exacerbations, co-morbidities and health care utilization, as compared to subjects with either 
disease alone.[7-10]  
According to some authors, ACOS is a syndrome in which older adults, generally with a significant 
history of smoking, have a partially reversible or fixed airflow obstruction and evidence of atopy or 
asthma.[11] It is still an open question whether ACOS is the result of asthma that has progressed to 
fixed airflow obstruction, or the expression of COPD in patients with airway hyperresponsiveness 
(AHR), or a specific disease entity.[12, 13] 
Few epidemiological studies have investigated the joint epidemiological distribution of asthma and 
COPD in the general population, as well as the long-term outcomes of ACOS.[5, 11, 14] Indeed, 
ACOS is often an exclusion criterion in studies investigating asthma or COPD.[9, 15]  
 The aims of this prospective study were to assess, in an international cohort of young adults from 
the general population participating in the European Community Respiratory Health Survey 
(ECRHS), whether clinical characteristics and risk factors, long-term lung function decline and risk 
of being admitted to hospital or Emergency Room (ER) vary among subjects with asthma, COPD 







Study design  
The ECRHS I was an international multicentre study performed between 1991 and 1993 on random 
samples of young adults (20–44 yr) from the general population (www.ecrhs.org).[16] From those 
who responded to a screening questionnaire (stage 1), a 20% “random sample” and an additional 
‘‘symptomatic sample’’ (subjects with recent asthma-like symptoms or use of asthma medication) 
were selected for a clinical examination (stage 2), which is called the “baseline” examination from 
now on. All participants in stage 2 were invited to take part in the “follow-up” examination 
(ECRHS II) between 1999 and 2002.[17] Ethical approval was obtained for each centre from 
institutional or regional ethics committees and written consent was obtained from the participants. 
The maximum pre-bronchodilator FEV1 and FVC were measured at both surveys.[18] Chronic 
airflow obstruction was defined as a pre-bronchodilator FEV1/FVC< lower limit of normal (LLN) 
both at baseline and at follow-up.[19] Transient airflow obstruction was defined as a 
FEV1/FVC<LLN at baseline but not at follow-up. Predicted lung function values were 
computed.[20] Airway hyperresponsiveness (AHR) was defined as a FEV1 decrease of 20% after a 
cumulative methacholine dose ≤1 mg. Allergen sensitization was present if levels of serum 
immunoglobulin E for house dust mite, cat dander, timothy grass, or Cladosporium species were 
>0.35 kU/L. Body height and weight were measured and body mass index (BMI) was computed 
(kg/m2). 
Definitions 
At baseline, a subject was considered to have current asthma if: 
1) she/he reported to have or have had asthma AND one among:  
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 asthma-like symptoms (wheezing/whistling in the chest; chest tightness; shortness of breath at 
rest/following strenuous activity/at nighttime; asthma attacks)  
 use of inhaled/oral medicines for breathing problems in the last year  
 AHR  
 transient airflow obstruction.  
OR  
2) she/he reported asthma-like symptoms in the last year AND she/he had AHR. 
Since post-bronchodilator spirometry was not performed in ECRHS I and II, a subject was 
considered to have COPD at baseline if she/he had pre-bronchodilator chronic airflow obstruction 
AND one among: 
 symptoms (shortness of breath after strenuous activity, or dyspnoea [trouble with breathing], or 
chronic bronchitis [having cough or phlegm on most days for as long as three months each year 
for ≥2 years])  
 a history of active smoking (≥10 pack-years),[21] or occupational exposure to vapours, dust, gas 
or fumes (indicated by a positive answer to “Have you ever worked in a job which exposed you 
to vapors, gas, dust or fumes?”).  
The validity of our definition of pre-bronchodilator chronic airflow obstruction was assessed using 
preliminary post-bronchodilator lung function data collected in ECRHS III (2010-2014). The 
findings (see section 1 of the online supplementary material) suggest that “chronic airflow 
obstruction” is a valid measurement of fixed airflow obstruction (sensitivity = 80.2%, specificity = 
98.3%), and that the rate of misclassification is very similar for subjects with and without asthma 
(positive predictive value = 73.9% and 69.3%, respectively). 
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Finally, subjects were classified into four mutually exclusive groups at baseline:[5] 1) “healthy” 
subjects (neither current asthma nor COPD); 2) current asthma alone (asthma without COPD); 3) 
ACOS (both current asthma and COPD); 3) COPD alone (COPD without asthma). 
A similar classification was applied at follow-up to evaluate whether the disease status was stable 
over the study period (see section 2 of the online supplementary material).  
The longitudinal outcomes were:  
 absolute FEV1 (and FVC) change over follow-up [(value follow-up – value baseline) / follow-up 
time] (mL/year); and FEV1 (and FVC) change as a percentage of baseline value [100 x 
(value follow-up – value baseline) / (value baseline x follow-up time)] (%/year). Negative values 
represent decline. 
 risk (%) of hospitalizations and/or Emergency Room (ER) visits because of breathing 
problems over follow-up. 
Statistical analysis 
Prevalence of risk factors and clinical characteristics at baseline (as defined in Tables 2 and 3, also 
see section 3 of the online supplementary material) were adjusted for sex and age (continuous 
variable) by logistic regression. Multiple linear and logistic regression models were fitted to data 
using lung function change and hospitalization rates as dependent variables, respectively, and 
disease status as the main independent variable. Adjustment variables were age, height, BMI 
(treated as continuous variables), sex, education, occupational exposure at baseline; lifetime 
smoking exposure and BMI change over time. All models included a random intercept for ECRHS 
centres and type of sample (random vs. symptomatic).[22] Missing values were deleted listwise. 
The statistical analyses were performed using STATA 13.1 (StataCorp, College Station, TX). 
In sensitivity analyses: 
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a) asthma was defined as a positive answer to “have you ever had asthma?” (self-reported asthma) 
at baseline and COPD was defined as the presence of chronic airflow obstruction (disregarding 
the presence of symptoms and exposures). 




A total of 18,356 subjects from 29 centres in 14 countries participated in the ECRHS I stage 2 
(1991–1993: baseline), of whom 15,716 (86%) were from the random sample (Figure 1). Overall, 
10,933 (60%) subjects attended the second survey, of whom 9,175 (84%) were from the random 
sample. Subjects participating in ECRHS II were older, less likely to have ever smoked and had 
better lung function at baseline than subjects who did not (Table S4 in the Supporting information). 
Mean follow-up time was 9±1 (range: 4–12) years. Among participants in the second survey who 
had data on lung function and asthma, 5,659 “healthy” subjects, 941 subjects with current asthma 
alone, 218 subjects with ACOS, and 166 subjects with COPD alone were identified, while 131 
subjects could not be classified (see note of Figure 1). The distribution of subjects across the 
different sub-definitions of current asthma and COPD is reported in the online supplementary 
material (Table S5). 
Among participants in ECRHS II, the characteristics of the subjects included and not included in 
the analyses were similar, with the exception that the latter were slightly younger and more likely to 
have AHR (Table 1). The disease status was relatively stable over time (Table S3): the percentage 
of subjects that were classified, both at baseline and at follow-up, in the same disease group ranged 
between 75.7% (COPD alone) and 93.0% (healthy subjects). 
Baseline characteristics and risk factors  
Subjects with current asthma alone were younger (33.6±7.2 years on average) and more likely to be 
women than subjects in the other groups (Table 2), while subjects with COPD were the oldest 
(36.0±6.5 years). Smoking was more frequent among subjects with ACOS or COPD. Among 
lifetime smokers, the prevalence of heavy smoking (≥15 pack-years) was 51.5% for subjects with 
COPD alone (median [IQR]: 16.8 [15.9] pack-years), and it ranged from 27.1 (healthy, 9.8 [13.8] 
pack-years) to 35.1% (ACOS, 10.3 [20.1] pack-years) in the other groups (p<0.001). Occupational 
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exposures were reported more frequently in the COPD (57.4%) and asthma (45.9%) groups than in 
the reference category (42.0%) (p=0.001). Family asthma and childhood respiratory infections were 
the most frequent in subjects with asthma or ACOS (p<0.001).  
Information on asthma onset was available for 705 (74.9%) subjects with asthma alone and 170 
(78.0%) with ACOS. On average, subjects with ACOS had an earlier age of onset (14.9 vs 17.2 
years; p=0.016), a longer disease duration (27.7 vs 24.8 years; p=0.003), a greater percentage of 
inhaled corticosteroid use (30.2 vs 20.6%; p=0.003) and more frequent asthma attacks in the last 
year (11.2 vs 6.2; p=0.034).  
The prevalence rates of wheezing, dyspnoea, chronic bronchitis, allergic rhinitis, eczema, allergen 
sensitization, as well as the use of medicines and hospital/ER admissions, were the highest for 
subjects with ACOS or current asthma alone (all p<0.001) (Table 3). The prevalence of AHR 
ranged from 3.5% (healthy) to 92.1% (ACOS) (p<0.001). Subjects with FEV1 <80% predicted 
were 4.5% for current asthma alone, 16.4% for COPD alone and 33.1% for the ACOS group 
(p<0.001).  
Change in lung function and risk of hospitalization  
Mean change in FEV1 and hospitalization rates at the follow-up are reported in Table 4. After 
adjusting for potential confounders (Table 5), subjects with COPD alone had a -7.64 (95%CI: -12.6; 
-2.66) mL/year greater change in FEV1 compared to healthy subjects (p=0.007), whereas their FVC 
change was -13.83 (95%CI: -19.96; -7.70) mL/year greater (<0.001). Lung function change was 
similar in asthma, ACOS and healthy subjects. Similar results were obtained when analysing 
change in lung function as a percentage of baseline value. Subjects with COPD alone, asthma alone, 
and ACOS, had a 2-fold, 4-fold, and 5-fold greater risk of reporting hospital/ER admissions over 




When the disease groups were identified according to alternative definitions of asthma (self-
reported asthma at baseline) and COPD (chronic obstruction), the distribution of risk factors and 
clinical characteristics were similar (Tables S6 and S7 in the online supplementary material), with 
the exceptions that the difference in smoking exposure between subjects with ACOS and healthy 
subjects, as well as the difference in occupational exposures between subjects with COPD and 
healthy subjects, shifted to the null. The results of the analyses on lung function change and 
hospitalization risk were fully confirmed both using these alternative definitions (Table S8), and 





The aim of this paper was to better understand the ACOS by investigating its similarities and 
differences with respect to asthma and COPD alone. This is one of the first studies investigating 
ACOS in an international population-based cohort. We studied young adults in an age range when 
disease evolution is still only minimally masked by the effects of cumulative exposure to risk 
factors and comorbidities.[23] We found that subjects with both asthma and COPD shared with 
asthmatic subjects risk factors and clinical characteristics, and had a 9-year lung function decline 
similar to subjects with asthma, significantly lower than in COPD.  
 
Clinical characteristics and risk factors 
Previous reports showing that subjects with ACOS have a pattern of risk factors that is intermediate 
between asthma and COPD, but more exacerbations and greater severity than subjects with either 
disease alone,[7, 24] raised the hypothesis that ACOS could be a specific disease entity.[12, 13, 25] 
As far as we know, studies on ACOS were usually cross-sectional and based on selected groups of 
elderly patients or medical record data, and collected limited clinical information.[8-10] It is 
therefore not surprising that our findings are only in partial agreement with previous evidence, as 
they point out that subjects with ACOS have the same clinical profile and risk factors as asthmatics 
(even if they represent a more severe subgroup), which was quite different from that of subjects 
with COPD. Indeed they shared the same prevalence of allergen sensitization, allergic rhinitis and 
eczema with asthmatics. Almost all of them (92.1%) had AHR. Furthermore they had the same 
increased prevalence of family asthma history and childhood respiratory infections.[26] Like 
asthmatics, subjects with ACOS had a greater prevalence of respiratory symptoms, use of medicines 
and hospital/ER admissions than young COPD patients. With respect to other asthmatics, subjects 
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with ACOS had an earlier onset and a longer duration of asthma, a higher frequency of smoking 
and a higher prevalence of males.  
In agreement with previous studies on the general population,[27] and in contrast with clinical 
studies on older patients,[9] we found that subjects with ACOS had worse lung function at baseline 
than subjects with asthma or COPD alone. With respect to other asthmatics, this result may reflect 
airway remodelling or a failure to attain maximal airway growth because of an early disease 
onset,[23] or both. Indeed, a correlation between disease duration and airway remodelling has been 
reported.[28] The poorer lung function with respect to COPD is probably due to the fact that the 
effect of the exposures that lead to COPD can only be recognized at older ages.[29]  
In the main analyses, definitions of active asthma and COPD were adopted by using information on 
current symptoms or exposures. For this reason, the distribution of some symptoms and risk factors 
may have depended on the definitions used. However, when we adopted alternative definitions of 
asthma and COPD that did not consider the presence of symptoms and risk factors, the distribution 
of characteristics across disease groups was very similar, with a few exceptions regarding smoking 
and occupational exposures. In a joint statement of GINA and GOLD,[2] ACOS is defined as 
“persistent airflow limitation with several features usually associated with asthma and several 
features usually associated with COPD”. Accordingly, ACOS was defined as the overlap between 
asthma and COPD in our study. Thus, it is worth noting that different distributions of characteristics 
in ACOS vs. asthma (or ACOS vs. COPD) did not depend on the definitions used, but they 
reflected peculiarities of ACOS as compared to asthma or COPD alone. 
Change in lung function and risk of hospitalization  
While COPD is characterized by an accelerated, although variable FEV1 decline,[21] many 
asthmatic patients experience a slow decline.[30] Accordingly, our findings document that subjects 
with asthma alone had a 9-year decline in lung function that was not different from that of people 
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without respiratory diseases. Subjects with ACOS, who had the poorest FEV1 and FVC at baseline, 
had a similar FEV1 and FVC decline to subjects with asthma, but a significantly lower decline than 
in COPD. One explanation is that the mechanisms and pathways of airflow obstruction in ACOS 
and COPD may be different. In the ACOS group, they may be due to acquired deficits in lung 
growth very early in life,[26] while in COPD they are mainly due to a steeper decline in adult life 
because of risk factor exposure. The younger age at asthma onset in subjects with ACOS in our 
study is consistent with this hypothesis. The very high prevalence of AHR in ACOS also fits this 
picture. In fact, AHR is associated with COPD and worse lung function, even when AHR is 
measured extremely early in life.[31, 32]. Alternatively, subjects with ACOS may have had a severe 
insult or more frequent exacerbations early in life, which may have caused a significant impairment 
in lung function that is no longer progressive. However, this might be at least in part due to the 
efficacy of treatments in preventing lung function deterioration in asthma.[33] To our knowledge, 
there are only two other longitudinal studies comparing lung function decline of subjects with 
ACOS, asthma and COPD.[8, 34] Both are clinical studies on older patients and used different 
disease definitions compared to our study, and the samples investigated were smaller and not 
representative of the vast majority of cases in the general population. Results from the most recent 
of these two studies support our conclusion,[34] while the other found that lung function decline in 
ACOS patients was more similar to that of COPD patients, and greater than in asthma patients.[8]  
In agreement with previous clinical studies,[10, 26, 35] our population study showed that ACOS 
subjects, who had the lowest FEV1 % predicted at baseline, had a rate of hospital/ER admissions 
for breathing problems during the follow-up that was more than double with respect to subjects with 
either disease alone. Indeed, asthma with fixed airflow obstruction is one of the main clinical 
phenotypes of uncontrolled severe asthma,[36] characterized by a poor prognosis and recurrent 
exacerbations, and reduced FEV1 is an important risk factor for multiple exacerbations both in 
asthma and COPD.[37]  
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Study limitations  
Like in many other large-scale surveys started in the nineties, post-bronchodilator spirometry was 
not available. As a consequence, some asthmatic subjects with fully reversible obstruction could 
have been falsely classified as COPD. To minimize this bias, we used chronic airflow obstruction 
(pre-bronchodilator FEV/FVC< LLN in both studies, nine years apart) as a spirometric criterion of 
COPD. A pilot evaluation, based on preliminary post-bronchodilator lung function data of ECRHS 
III (2010-2014), supports the validity of pre-bronchodilator chronic airflow obstruction as an 
indicator of fixed obstruction. In fact, sensitivity and specificity were 76.7 and 98.8%, respectively, 
in subjects without asthma, and 86.4 and 94.3%, respectively, in subjects with asthma (Table S1 in 
the online supplementary material). This supports the fact that our definition of chronic airflow 
obstruction captured the majority of subjects with “true” post-bronchodilator obstruction, and that it 
excluded virtually all subjects without. Moreover, high and fairly similar positive predictive values 
for subjects with (73.9%) and without (69.3%) asthma suggest non-differential misclassification, 
strengthening the validity of comparisons between subjects with ACOS and subjects with COPD 
alone.  
Either respiratory symptoms and/or active smoking/occupational exposures were necessary, in 
combination with the spirometrical criterion, to define COPD.[2, 21] This resulted in a more 
specific definition as compared to the definition based on spirometry alone.[38] Longitudinal 
studies with post-bronchodilator lung function data will be needed to adequately compare the level 
and severity of airflow obstruction in subjects with ACOS and COPD. 
Since the study aim was not to estimate disease prevalence in the population but to compare 
characteristics across disease groups, this analysis included both a random subsample of 
respondents and all the subjects who reported symptoms suggestive of asthma at the screening 
questionnaire. As a consequence of the random sampling of the population participating at ECRHS 
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stage 1, however, the subjects from the disease groups investigated are representative of the disease 
in the population.  
Unfortunately information on inflammatory markers to characterize the ACOS phenotypes was not 
available in our study.[13] Finally, the participation rate was not particularly high. However, the 
comparison of baseline information between subjects who did and did not participate showed that 
the two groups were similar. 
 
Conclusion 
Our findings suggest that, at least among young adults aged 20-44 years, the asthma-COPD overlap 
syndrome represents a form of severe asthma, characterized by more frequent exacerbations, and it 
is likely to be the result of early asthma that has progressed to fixed airflow obstruction, possibly 
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Figure 1: Number of subjects included in the analyses. 
 
ACOS, asthma-COPD overlap syndrome 
* for 3,810 subjects spirometry was not available either at baseline and/or follow-up, and 8 subjects 
did not answer the question on asthma at baseline 
† subjects who reported asthma at baseline but did not fulfil the criteria for current asthma (n=67), 
and subjects who had chronic airflow obstruction but did not fulfil the criteria for COPD (n=64), 









































in the analyses 
(n= 3,949) 
p-value 
Female gender (n, %) 3,708 (53) 2,100 (53) 0.93 
Age (yr)* 34.3 (7.1) 33.7 (7.2) <0.001 
BMI (kg/m2)* 24.1 (4.0) 24.1 (4.0) 0.53 
Low education (n, %) 875 (13) 499 (13) 0.83 
Smoking habits (n, %) 
non-smoker 
< 15 pack-years 










Sensitization to  
allergens (n, %) 
2,130 (34) 970 (35) 0.49 
FEV1 % predicted* 105.0 (13.5) 105.0 (15.2) 0.95 
AHR (n, %)  886 (15) 398 (18) 0.001 

















Female gender (%) 52.2 (50.8-53.6) 61.2 (58.0-64.3)*** 47.7 (41.0-54.3)  47.5 (39.9-55.2) <0.001 
Age (>35 y) (%) 50.8 (47.8-53.7)  44.2 (40.1-48.2)** 50.5 (43.2-57.7) 60.4 (52.5-68.3)* <0.001 
Low education (%) 6.7 (3.7-9.8) 7.4 (3.8-11.0)  7.9 (3.3-12.5) 7.0 (2.4-11.7) 0.80 
Lifetime smoker (>0 vs. 0 
pack-years smoked) (%) 
55.1 (52.6-57.7) 56.5 (52.6-60.3) 64.1 (57.3-70.9)* 72.4 (65.1-79.7)*** <0.001 
Heavy smoker (≥15 vs. 0.1-
14.9 pack-years smoked) 
(%)†† 
27.1 (24.1-30.1) 30.2 (25.1-35.2) 35.1 (26.0-44.3) 51.5 (40.6-62.3)*** <0.001 
ETS (%) 57.1 (52.1-62.0) 60.0 (54.3-65.7) 58.3 (49.9-66.7) 66.0 (57.2-74.4)* 0.084 
Occupational  
exposure (%) 
42.0 (37.2-46.7) 45.9 (40.2-51.6)* 43.7 (35.2-52.2) 57.4 (48.1-66.7)*** 0.001 
Family asthma (%) 11.1 (9.9-12.3) 24.9 (21.6-28.1)*** 26.3 (20.0-32.6)*** 18.4 (12.1-24.7)** <0.001 
Respiratory infection  
in childhood (%) 
8.7 (7.4-10.1) 17.4 (14.2-20.6)*** 20.0 (14.0-25.9)*** 13.0 (7.7-18.4) <0.001 
Mother smoking during  
subject’s childhood (%) 
18.6 (13.3-23.8) 19.1 (13.3-24.9) 20.3 (12.8-27.7) 17.5 (10.1-25.0) 0.89 
Cat in childhood (%) 47.9 (44.3-51.4) 47.8 (43.2-52.4) 45.0 (37.4-52.6) 55.6 (47.2-64.1) 0.22 
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Dog in childhood (%) 49.1 (44.3-53.8) 48.4 (42.8-54.0) 43.8 (35.5-52.1) 50.7 (41.4-59.9) 0.54 
Currently  
keeping a cat (%) 
17.6 (14.5-20.6) 20.9 (16.8-25.1)* 15.6 (10.3-21.0) 12.0 (6.7-17.3) 0.013 
Currently  
keeping a dog (%) 
15.6 (13.1-18.2) 18.1 (14.6-21.7) 17.1 (11.7-22.5) 10.9 (5.7-16.1) 0.092 
Mould in the house (%) 33.0 (28.4-37.6) 35.7 (30.1-41.3) 30.9 (23.1-38.6) 30.9 (22.1-39.7) 0.37 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† adjusted by using a logistic regression model with the characteristic in the 1st column as the dependent variable, sex, age (with the exception of sex 
and age, only adjusted for age and sex, respectively), and disease status as independent variables, and a random intercept term for ECRHS centre 
and sample 
‡ refers to the comparison across the groups. A p<0.05 indicates that at least one of the prevalence rates is significantly different from the others.  
















Wheezing in the last 
12months (%) 
22.1 (18.1-26.0) 77.9 (73.3-82.5)*** 87.3 (82.1-92.6)*** 38.2 (28.7-47.7)*** <0.001 
Trouble with  
breathing (%) 
23.1 (18.5-27.7) 70.5 (64.5-76.5)*** 79.2 (72.1-86.3)*** 35.3 (25.3-45.3)** <0.001 
MRC dyspnoea  
score >1†† (%) 
18.0 (15.0-21.1)  36.0 (30.5-41.4)*** 38.3 (29.9-46.7)*** 27.9 (19.5-36.3)** <0.001 
Chronic Bronchitis § (%) 11.1 (9.2-13.0) 25.0 (20.7-29.3)*** 30.6 (23.3-38.0)*** 22.9 (15.3-30.4)*** <0.001 
AHR (%) 3.5 (2.8-4.2) 66.6 (62.0-71.4)*** 92.1 (87.7-96.4)*** 14.5 (7.5-21.4)*** <0.001 
Allergic rhinitis (%) 24.1 (21.3-26.9) 60.5 (55.9-65.1)*** 55.5 (47.8-63.3)*** 24.7 (17.5-32.0) <0.001 
Lifetime eczema (%) 38.7 (35.3-42.1) 49.4 (44.8-54.0)*** 45.0 (37.5-52.6) 39.1 (30.9-47.4) <0.001 
Allergen  
sensitization (%) 
28.4 (25.7-31.1) 64.4 (60.2-68.6)*** 67.4 (60.1-74.7)*** 26.8 (19.1-34.4) <0.001 
Use of medicines 
(inhaler, oral, injection, 
suppository or other 
remedy) for breathing 
problems (%) 
20.3 (15.3-25.3) 71.2 (64.4-78.1)*** 75.8 (67.4-84.2)*** 22.2 (13.0-31.4) <0.001 
Hospital/ER admission 
for breathing problems 




FEV1 <80%  
predicted (%) 
1.4 (1.0-1.8) 4.5 (3.1-6.0)*** 33.1 (25.6-40.5)*** 16.4 (10.3-22.5)*** <0.001 
FVC <80%  
predicted (%) 
1.0 (0.6-1.3)  1.3 (0.5-2.0)  3.4 (1.1-5.8)** 1.3 (0.0-2.9) 0.024 
FEV1 % predicted 106.9 (105.9-107.9) 101.5 (100.3-102.7) *** 85.1 (83.2-86.9) *** 92.5 (90.5-94.6) *** <0.001 
FVC % predicted 109.0 (108.0-110.0) 106.9 (105.7-108.1) *** 107.6 (105.7-109.5) 112.3 (110.2-114.4) ** <0.001 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† adjusted by using a logistic regression model with the characteristic in the 1st column as the dependent variable, sex, age and disease status as 
independent variables, and a random intercept term for ECRHS centre and sample  
‡ refers to the comparison across the groups. A p<0.05 indicates that at least one of the prevalence rates is significantly different from the others 
†† being troubled by shortness of breath when hurrying on level ground or walking up a slight hill  

















Mean FEV1 change  
(mL/year) 
-26.2 (-31.1; -21.3) -25.3 (-30.5; -20.1) -25.9 (-32.2; -19.6) -37.3 (-44.0; -30.6)*** <0.001 
Mean FEV1 change  
(% of baseline/year) 
-0.69 (-0.83; -0.55) -0.68 (-0.83; -0.53) -0.66 (-0.84; -0.47) -1.17 (-1.37; -0.97)*** <0.001 
Mean FVC change  
(mL/year) 
-19.8 (-25.6; -14.1) -21.3 (-27.4; -15.2) -25.5 (-33.0; -18.0)* -37.0 (-45.0; -29.0)*** <0.001 
Mean FVC change  
(% of baseline/year) 
-0.42 (-0.55; -0.29) -0.45 (-0.59; -0.31) -0.55 (-0.72; -0.38)*  -0.81 (-0.99; -0.63)*** <0.001 
Hospital/ER admission for 
breathing problems§ (%) 
3.6 (2.7; 4.5) 11.9 (8.7; 15.0)*** 15.8 (9.9; 21.8)*** 8.1 (3.5; 12.7)** <0.001 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† adjusted by using a linear regression model, with FEV1 or FVC change as dependent variable, sex, age, height and disease status as independent 
variables, and a random intercept term for ECRHS centre and sample. A negative value represents lung function decline 
‡ adjusted by using a logistic regression model, with hospital/ER admissions as dependent variable, sex, age and disease status as independent 
variables, and a random intercept term for ECRHS centre and sample 
†† refers to the comparison across the groups 
§ present if a subject answered positively to one or both the questions “Since the last survey, have you spent a night in hospital / have you visited a 
hospital casualty department or ER because of breathing problems?”   
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Table 5. Mean change of lung function† and risk of hospital/ER admission for breathing problems‡ over the follow-up, with 95%CIs, for subjects 
with current asthma, COPD or both, compared with healthy subjects. 
  
 Asthma alone ACOS COPD alone 
p-value 
heterogeneity†† 




respect to the 
healthy category 
 
0.69 (-1.65; 3.02) 1.62 (-2.76; 5.99)  -7.64 (-12.6; -2.66)** 0.007 
FEV1 change  
(% of baseline/year) 
0.004 (-0.07; 0.07) 0.05 (-0.08; 0.18) -0.37 (-0.52; -0.22)*** <0.001 
FVC change  
(mL/year) 
-0.92 (-3.79; 1.96) -4.84 (-10.23; 0.54) -13.83 (-19.96; -7.70)*** <0.001 
FVC change  
(% of baseline/year) 
-0.01 (-0.08; 0.05) -0.11 (-0.23; 0.01) -0.30 (-0.43; -0.16)*** <0.001 
Hospital/ER admission for 
breathing problems§  
OR (95%CI) 
with respect to 
the healthy 
category 
3.76 (2.84; 4.99)*** 5.12 (3.24; 8.10)*** 2.10 (1.06; 4.13)* 0.080 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† regression coefficients obtained by using a linear regression model, with FEV1 or FVC change as dependent variable, sex, age, height, BMI, 
education level, occupational exposure to vapours, gas, dust or fumes, disease status at baseline; lifetime smoking exposure (5-level variable coded 
as: 0, lifetime non-smoker; past-smoker with 1, <15 p-y smoked or 2, ≥15 p-y smoked; current smoker with 3, <15 p-y smoked or 4, ≥15 p-y 
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smoked) and change in BMI over the follow-up as independent variables, and a random intercept term for ECRHS centre and sample. A negative 
value represents a greater decline with respect to the healthy reference category 
‡ ORs obtained by using a logistic regression model, with hospital/ER admissions as dependent variable, sex, age, BMI, education level, 
occupational exposure to vapours, gas, dust or fumes, disease status at baseline; lifetime smoking exposure, and change in BMI over the follow-up 
as independent variables, and a random intercept term for ECRHS centre and sample 
†† p-value for the heterogeneity of the association across the groups, obtained by testing the difference across regression coefficients using Wald 
test. A p<0.05 indicates that at least one of the regression coefficients is significantly different from the others, i.e. that the change in lung function 
(or risk of hospital/ER admissions) with respect to the reference healthy category differs for at least one disease group as compared to the others  
§ present if a subject answered positively to one or both the questions “Since the last survey, have you spent a night in hospital / have you visited a 
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1) Validity of the definition of chronic airflow obstruction 
The European Community Respiratory Health Survey (ECRHS) III is a follow-up prospective 
survey (2010-2014) of all subjects who underwent examination in ECRHS I (www.ecrhs.org). The 
maximum FEV1 and FVC before and 15 min after the administration of a bronchodilator 
(Salbutamol, 400 μg) were measured. All study participants gave their written informed consent. 
We evaluated the validity of the definition of chronic airflow obstruction using preliminary lung 
function data from the ECRHS III. We defined chronic airflow obstruction at ECRHS III (present if 
pre-bronchodilator FEV1/FVC <lower limit of normal [LLN] both at ECRHS II and at ECRHS III; 
absent if pre-bronchodilator FEV1/FVC ≥LLN at ECRHS III). The “gold standard” for comparison 
was fixed airflow obstruction at ECRHS III defined according to post-bronchodilator spirometry 
(FEV1/FVC< LLN). The LLN was defined according to the reference values by Kuster et al. 
(2008), which have been derived for an age range (18-80 years) that includes the ages of all subjects 
participating in ECRHS between 1991 and 2014.  
We included in the analysis all the 3,287 subjects who participated both in ECRHS II and ECRHS 
III and had pre- and post-bronchodilator lung function measurements available (2,911 without 
asthma + 376 with asthma) (Table S1). We repeated this analysis using the GOLD fixed cut-off 






Table S1: Validity* of the definition of pre-bronchodilator chronic airflow obstruction as compared 

















2,911 103 76.7 98.8 69.3 99.1 
Subjects 
with asthma 
376 59 86.4 94.3 73.9 97.4 
* analysis based on ECRHS III preliminary lung function data.  
 
Table S2: Validity* of the definition of pre-bronchodilator chronic airflow obstruction as compared 

















2,786 123 73.2 98.8 74.4 98.8 
Subjects 
with asthma 
361 65 86.2 95.6 81.2 96.9 





2) Stability of disease definitions over time 
To evaluate whether disease status was stable over the study period, we re-assessed subjects’ 
disease status at follow-up. Subjects were classified at follow-up (ECRHS II) using similar 
definitions of current asthma, COPD, and the ACOS that we used at baseline (ECRHS I) (see 
Methods of the manuscript), and then their disease status at baseline and follow-up were compared. 
For disease classification at follow-up, we used data on asthma, respiratory symptoms, AHR and 
use of medicines derived from ECRHS II (to account for current disease manifestations). 
Information on history of active smoking or occupational exposures were derived combining data 
from ECRHS I and II (to account for cumulative exposures). The definition of chronic airflow 
obstruction was the same (pre-bronchodilator FEV1/FVC< LLN both at baseline and at follow-up). 
The results of this analysis are shown in Table S3. Information to classify disease status at both 
surveys was available for 6,859 (98%) subjects. Most of the subjects that were in one disease group 
at baseline were still classified in the same disease group at follow-up: percentages of subjects with 
unchanged classification ranged between 75.7% (COPD alone) and 93.0% (healthy subjects). Most 
subjects with ACOS were still classified in this group at follow-up (83.9%), while some were re-
classified as having current asthma alone (3.3%) or COPD alone (12.8%). 
 
Table S3: comparison of the disease status at baseline and follow-up. 
  Disease status at follow-up  
 
 


























































3) Questionnaire information 
Based on the answers to the questions of the clinical interview, the following variables were derived 
for each subject:  
- age and sex; 
- lifetime asthma (positive answer to the question “Have you ever had asthma?”); 
- asthma-like symptoms in the last 12 months (wheezing or whistling in the chest; chest tightness; 
shortness of breath at rest; shortness of breath following strenuous activity, woken up by shortness 
of breath);  
- use of inhaled/oral medicines to help breathing in the last 12 months; 
- chronic bronchitis (having cough or phlegm on most days for as long as three months each year 
for ≥2 years); 
- a Medical Research Council (MRC) dyspnea score >1 (being troubled by shortness of breath when 
hurrying on level ground or walking up a slight hill); 
- allergic rhinitis (the presence of nasal allergies, including hay fever); 
- lifetime eczema (having ever had eczema or any kind of skin allergy); 
- a low education level (having completed full-time education before the age of 16); 
- occupational exposure to vapors, gas, dust or fumes (positive answer to “Have you ever worked in 
a job which exposed you to vapors, gas, dust or fumes?); 
- lifetime smoking exposure: 0) lifetime non-smoker; past-smoker with 1) <15 p-y smoked or 2) 
≥15 p-y smoked; current smoker with 3) <15 p-y smoked or 4) ≥15 p-y smoked; 
- environmental tobacco smoke (ETS) exposure (having been regularly exposed to tobacco smoke 
in the last 12 months);  
- family asthma (having reported asthma in father and/or mother); 
- respiratory infection in childhood (having had a serious respiratory infection before the age of five 
years); 
- having a mother who smoked regularly during childhood or before the subject was born; 
- exposure to cat/dog in childhood (anyone in the household kept a cat/dog during subject’s 
childhood); 
- currently keeping a cat/dog; 
- mold in the house (positive answer to “Has there ever been any mold or mildew on any surface, 
other than food, inside the home?”); 
- hospitalization or Emergency Room (ER) visits for respiratory problems during the follow-up 
(positive answer to one or both of the  questions “Since the last survey, have you spent a night in 




Table S4: Baseline (ECRHS I) characteristics of the subjects according to their participation in 
ECRHS II.  
 
Non-participating  
in ECRHS II 
(n=7,423) 
Participating  
in ECRHS II 
 (n=10,933) 
p-value 
Female gender (n, %) 3,878 (52) 5,808 (53) 0.24 
Age (yr)* 33.2  7.2 34.1  7.1 <0.001 
Body mass  
index  (kg/m2)* 
23.9 4.1 24.1  4.0 0.006 
Low education (n, %) 767 (13) 1,374 (13) 0.91 
Smoking habits (n, %) 
non-smoker 
< 15 pack-yrs 










Sensitization to  
allergens (n, %) 
1,763 (35) 3,100 (34) 0.30 
FEV1 % predicted* 103.9  14.4 105.0  14.0 <0.001 
Airway hyper-
responsiveness (n, %)  
758 (17) 1,284 (16) 0.28 














Current asthma  
“ever asthma” + asthma-like 
symptoms/asthma attacks 
666 (70.8%) 169 (77.5%) - 
“ever asthma” + medicines 
for breathing problems  
541 (57.5%) 148 (67.9%) - 
“ever asthma” + AHR 317 (33.7%) 87 (39.9%) - 
“ever asthma” + transient 
airflow obstruction 
84 (8.9%) - - 
asthma-like symptoms + 
AHR 
511 (54.3%) 131 (60.1%) - 
COPD  
chronic airflow obstruction + 
history of symptoms  
- 199 (91.3%) 93 (56.0%) 
chronic airflow obstruction + 
history of exposures 
- 149 (68.3%) 139 (83.7%) 
a subjects can fulfil more than one sub-definition of current asthma or COPD (e.g. subjects with 
“ever asthma” + asthma-like symptoms + use of respiratory medicines will fulfil both the first and 








Table S6. Sex- and age- adjusted prevalence rates with 95%CIs of socio-demographic characteristics, environmental exposures and risk factors at 












Female gender (%) 52.8 (51.3-54.2) 59.1 (55.6-62.6)** 46.9 (39.6-54.2)  54.0 (48.1-60.0) 0.003 
Age (>35 y) (%) 50.6 (47.6-53.5)  44.1 (39.8-48.5)** 45.8 (37.9-53.6) 56.1 (49.6-62.6) 0.002 
Low education (%) 6.9 (3.8-10.0) 6.4 (3.1-9.7)  6.4 (2.3-10.5) 7.7 (3.3-12.2) 0.88 
Lifetime smoker (>0 vs. 0 
pack-years smoked) (%) 
56.1 (53.6-58.6) 51.1 (46.9-55.3)* 58.5 (50.8-66.1) 65.0 (58.9-71.1)** 0.001 
Heavy smoker (≥15 vs. 0.1-
14.9 pack-years smoked) 
(%)†† 
28.2 (25.1-31.2) 25.2 (20.0-30.4) 27.0 (17.6-36.4) 45.4 (36.6-54.3)*** <0.001 
ETS (%) 58.1 (53.3-63.0) 56.3 (50.3-62.3) 52.9 (43.7-62.1) 60.4 (52.8-68.0) 0.44 
Occupational  
exposure (%) 
42.2 (37.4-46.9) 46.2 (40.2-52.2)* 43.6 (34.4-52.8) 40.2 (32.5-47.8) 0.28 
Family asthma (%) 11.4 (10.2-12.6) 26.2 (22.6-29.8)*** 29.7 (22.6-36.9)*** 17.5 (12.7-22.3)** <0.001 
Respiratory infection  
in childhood (%) 
8.7 (7.4-10.0) 19.9 (16.2-23.5)*** 20.7 (14.1-27.3)*** 12.1 (8.0-16.2) <0.001 
Mother smoking during  
subject’s childhood (%) 
18.9 (13.6-24.2) 18.8 (13.0-24.6) 17.5 (10.4-24.7) 18.9 (12.0-25.7) 0.97 
Cat in childhood (%) 48.1 (44.6-51.7) 46.1 (41.2-50.9) 45.2 (37.0-53.5) 50.0 (43.0-56.9) 0.63 
Dog in childhood (%) 49.3 (44.5-54.1) 46.8 (40.9-52.6) 42.1 (33.3-51.0) 50.5 (42.8-58.3) 0.25 
Currently  
keeping a cat (%) 
18.0 (14.9-21.2) 19.5 (15.3-23.7) 14.2 (8.7-19.6) 16.0 (11.0-21.1) 0.26 
Currently  
keeping a dog (%) 
15.9 (13.4-18.5) 17.7 (14.0-21.4) 15.7 (10.1-21.3) 11.9 (7.6-16.2) 0.17 
Mould in the house (%) 33.9 (29.1-38.6) 32.7 (27.1-38.4) 30.2 (22.0-38.4) 32.3 (24.8-39.9) 0.74 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
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† Asthma alone = reported to have ever had asthma; COPD alone = chronic airflow obstruction; ACOS = asthma + COPD; Healthy = neither 
asthma nor COPD. Same statistical analysis done in Table 2 of the manuscript 
‡ refers to the comparison across the groups.  

















Wheezing in the last 
12months (%) 
25.5 (21.0-30.0) 72.7 (67.1-78.3)*** 86.9 (80.9-93.0)*** 42.5 (34.1-51.0)*** <0.001 
Trouble with  
breathing (%) 
25.1 (20.1-30.1) 71.8 (65.7-78.0)*** 83.2 (76.2-90.2)*** 31.0 (22.7-39.3) <0.001 
MRC dyspnoea  
score >1†† (%) 
18.7 (15.5-21.9)  35.7 (29.8-41.5)*** 39.3 (30.2-48.5)*** 25.4 (18.6-32.1)* <0.001 
Chronic Bronchitis § (%) 11.9 (9.8-13.9) 23.9 (19.4-28.4)*** 29.0 (21.2-36.8)*** 19.3 (13.5-25.2)** <0.001 
AHR (%) 8.7 (7.1-10.2) 48.1 (42.3-53.9)*** 84.0 (76.3-91.7)*** 38.5 (30.4-46.6)*** <0.001 
Allergic rhinitis (%) 25.0 (22.1-27.8) 64.3 (59.6-69.0)*** 63.1 (55.0-71.3)*** 24.6 (18.8-30.4) <0.001 
Lifetime eczema (%) 38.8 (35.5-42.2) 50.8 (46.0-55.7)*** 47.9 (39.6-56.2)* 37.1 (30.5-43.7) <0.001 
Allergen  
sensitization (%) 
29.4 (26.7-32.1) 66.9 (62.5-71.3)*** 75.6 (68.4-82.9)*** 30.5 (24.2-36.9) <0.001 
Use of medicines 
(inhaler, oral, injection, 
suppository or other 
remedy) for breathing 
problems (%) 
21.8 (16.4-27.1) 74.4 (67.7-81.1)*** 84.5 (77.3-91.6)*** 26.1 (17.5-34.7) <0.001 
Hospital/ER admission 
for breathing problems 
(%) 
5.0 (3.9-6.1) 27.8 (22.5-33.1)*** 35.5 (26.7-44.3)*** 6.3 (3.1-9.5) <0.001 
FEV1 <80%  
predicted (%) 
1.4 (1.1-1.8) 4.4 (2.9-6.0)*** 37.9 (29.6-46.1)*** 14.9 (10.2-19.6)*** <0.001 
FVC <80%  
predicted (%) 
1.0 (0.6-1.3)  1.3 (0.5-2.0)  4.1 (1.3-7.0)*** 0.9 (0.0-1.8) 0.008 
FEV1 % predicted 106.5 (105.4-107.5) 102.4 (101.1-103.7)*** 84.3 (82.2-86.3)*** 92.7 (91.0-94.5)*** <0.001 
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FVC % predicted 108.8 (107.8-109.8) 107.3 (106.0-108.6)** 107.5 (105.5-109.6) 112.3 (110.5-114.0)*** <0.001 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† Asthma alone = reported to have ever had asthma; COPD alone = chronic airflow obstruction; ACOS = asthma + COPD; Healthy = neither 
asthma nor COPD. Same statistical analysis done in Table 3 of the manuscript 
‡ refers to the comparison across the groups.  
†† being troubled by shortness of breath when hurrying on level ground or walking up a slight hill  






Table S8: Mean change of lung function and risk of hospital/ER admission for breathing problems over the follow-up, with 95%CIs, for subjects 
with asthma, COPD or both, compared with healthy subjects: sensitivity analysis based on alternative disease definitions.†  
 
 Asthma alone ACOS COPD alone 
p-value 
heterogeneity†† 




respect to the 
healthy category 
 
-0.93 (-3.47; 1.60) 3.30 (-1.48; 8.07)  -4.89 (-8.72; -1.07)* 0.027 
FEV1 change  
(% of baseline/year) 
-0.04 (-0.11; 0.04) 0.12 (-0.03; 0.26) -0.25 (-0.37; -0.14)*** <0.001 
FVC change  
(mL/year) 
-2.49 (-5.60; 0.61) -3.62 (-9.50; 2.26) -10.90 (-15.61; -6.19)*** 0.010 
FVC change  
(% of baseline/year) 
-0.05 (-0.11; 0.02) -0.09 (-0.22; 0.04) -0.23 (-0.34; -0.13)*** 0.010 
Hospital/ER admission for 
breathing problems§  
OR (95%CI) 
with respect to 
the healthy 
category 
3.81 (2.83; 5.13)*** 5.68 (3.52; 9.16)*** 1.97 (1.14; 3.38)* 0.010 
* p<0.05, ** p<0.01, *** p<0.001 for the comparison of the disease group with the “healthy” category 
† Asthma alone = reported to have ever had asthma; COPD alone = chronic airflow obstruction; ACOS = asthma + COPD; Healthy = neither 
asthma nor COPD. Same statistical analysis done in Table 5 of the manuscript 
†† p-value for the heterogeneity of the association across the groups, obtained by testing the difference across regression coefficients by using Wald 
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